Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Myungsun | - |
dc.contributor.author | Bang, Woo Jin | - |
dc.contributor.author | Oh, Cheol Young | - |
dc.contributor.author | Lee, Yong Seong | - |
dc.contributor.author | Cho, Jin Seon | - |
dc.date.accessioned | 2024-07-01T02:00:39Z | - |
dc.date.available | 2024-07-01T02:00:39Z | - |
dc.date.issued | 2019-07 | - |
dc.identifier.issn | 2466-0493 | - |
dc.identifier.issn | 2466-054X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74444 | - |
dc.description.abstract | Purpose: To investigate the changes in testosterone levels and rates of chemical castration following androgen-deprivation therapy (ADT) with goserelin, triptorelin, and leuprolide. Materials and Methods: We retrospectively reviewed the medical records of 125 patients with prostate cancer treated with luteinizing hormone-releasing hormone (LHRH) agonists between January 2009 and December 2015. Changes in testosterone concentration during 9 months of ADT with goserelin 11.34 mg, triptorelin 11.25 mg, and leuprolide 11.25 mg were analyzed using a mixed model. The number of patients with serum testosterone below castration levels defined as various values (<50 ng/dL, <20 ng/dL, or <10 ng/dL) at 3, 6, and 9 months were also evaluated. Results: Of the 125 patients, 59 received goserelin, 44 received triptorelin, and 22 received leuprolide, respectively. The lowest mean testosterone levels during 9 months of treatment were achieved in patients treated with triptorelin, followed by those treated with leuprolide, and then by those treated with goserelin (p=0.001). Significant differences in chemical castration levels were observed only at <10 ng/dL, with 54.2% of goserelin, 93.2% of triptorelin, and 86.4% of leuprolide treated patients (p<0.001). Conclusions: Three LHRH agonists showed comparable efficacy for achieving castration when the castration threshold was 50 or 20 ng/dL. However, triptorelin was the most potent LHRH agonist, achieving the lowest mean testosterone levels and the highest rate of chemical castration at <10 ng/dL testosterone. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN UROLOGICAL ASSOC | - |
dc.title | Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide | - |
dc.type | Article | - |
dc.identifier.doi | 10.4111/icu.2019.60.4.244 | - |
dc.identifier.bibliographicCitation | INVESTIGATIVE AND CLINICAL UROLOGY, v.60, no.4, pp 244 - 250 | - |
dc.identifier.kciid | ART002484017 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000473353400004 | - |
dc.identifier.scopusid | 2-s2.0-85069180525 | - |
dc.citation.endPage | 250 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 244 | - |
dc.citation.title | INVESTIGATIVE AND CLINICAL UROLOGY | - |
dc.citation.volume | 60 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Antineoplastic agents | - |
dc.subject.keywordAuthor | Prostatic neoplasms | - |
dc.subject.keywordAuthor | Prostate-specific antigen | - |
dc.subject.keywordAuthor | Testosterone | - |
dc.subject.keywordPlus | ANDROGEN-DEPRIVATION THERAPY | - |
dc.subject.keywordPlus | TESTOSTERONE LEVELS | - |
dc.subject.keywordPlus | NADIR TESTOSTERONE | - |
dc.subject.keywordPlus | SERUM TESTOSTERONE | - |
dc.subject.keywordPlus | MEN | - |
dc.subject.keywordPlus | SUPPRESSION | - |
dc.subject.keywordPlus | SECRETION | - |
dc.subject.keywordPlus | PREDICTS | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | FAILURE | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.